<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053560</url>
  </required_header>
  <id_info>
    <org_study_id>GL02-01</org_study_id>
    <nct_id>NCT00053560</nct_id>
  </id_info>
  <brief_title>To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids</brief_title>
  <official_title>A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genelabs Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genelabs Technologies</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to study the effects of GL701 on bone mineral density&#xD;
      in women with active systemic lupus erythematosus (SLE) who are also receiving treatment with&#xD;
      glucocorticoids (e.g., prednisone).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2002</start_date>
  <completion_date>August 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>155</enrollment>
  <condition>Lupus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasterone (GL701)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Women at least 18 years of age.&#xD;
&#xD;
          -  Meet ACR criteria for diagnosis of SLE.&#xD;
&#xD;
          -  Concomitant treatment with prednisone at a dose of ≥5 mg/day over the last 30 days&#xD;
             prior to Screening visit.&#xD;
&#xD;
          -  Cumulative history of oral glucocorticoid use for at least 6 months over the last year&#xD;
             prior to the Screening Visit (the 6 months do not have to be consecutive).&#xD;
&#xD;
          -  Patient has lumbar spine and proximal femur anatomy suitable for measurement by DXA&#xD;
             with at least 3 evaluable vertebrae from L1 to L4.&#xD;
&#xD;
          -  SLEDAI ≥3 at the Qualifying Visit.&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative serum pregnancy test (at the&#xD;
             Screening Visit) and agree to use a reliable form of birth control while participating&#xD;
             in the study.&#xD;
&#xD;
          -  Patient is fully ambulatory.&#xD;
&#xD;
          -  Patient has read and signed an Informed Consent Form.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  History of breast cancer or malignancy of the reproductive tract organs.&#xD;
&#xD;
          -  History of any other cancers unless no evidence of disease for 5 years.&#xD;
&#xD;
          -  History of endometrial hyperplasia.&#xD;
&#xD;
          -  End stage renal disease or receiving hemodialysis treatment.&#xD;
&#xD;
          -  Any disease or condition that would preclude the accurate measurement of bone mineral&#xD;
             density of the lumbar spine or proximal femur by dual X-ray absorptiometry.&#xD;
&#xD;
          -  A T-score of less than or equal to - 2.5 of the L-spine or proximal femur at Screening&#xD;
             DXA assessment.&#xD;
&#xD;
          -  Unstable cardiac disease.&#xD;
&#xD;
          -  Conditions causing bone loss such as hyperparathyroidism, Cushing's disease,&#xD;
             thyrotoxicosis, chronic diarrheal state or malabsorption, renal tubular acidosis, or&#xD;
             anorexia nervosa.&#xD;
&#xD;
          -  Significant hepatic disease (i.e., cirrhosis).&#xD;
&#xD;
          -  Body mass index &gt; 35 kg/m2 or weight &gt;300 lbs.&#xD;
&#xD;
          -  Patients who are pregnant or breast feeding.&#xD;
&#xD;
          -  Patients who require glucocorticoids by an alternate day dosing schedule.&#xD;
&#xD;
          -  Known hypersensitivity to DHEA, or the inactive ingredients used in the GL701&#xD;
             formulation (cornstarch, lactose, magnesium stearate).&#xD;
&#xD;
          -  Known medical contraindication or hypersensitivity to Calcium/Vitamin D.&#xD;
&#xD;
          -  Participation in any prior DHEA or GL701 study.&#xD;
&#xD;
          -  Use of investigational agents within 30 days of the Screening Visit or 10 half-lives&#xD;
             of the agent.&#xD;
&#xD;
          -  Any condition which in the Investigator's or Sponsor's opinion is sufficient to&#xD;
             prevent adequate compliance with the study or likely to confuse follow-up evaluation&#xD;
             (e.g., alcoholism, drug addiction, acute withdrawal from chemical dependency,&#xD;
             psychiatric disease).&#xD;
&#xD;
          -  The patient is taking or has taken one of the medications listed below:&#xD;
&#xD;
        ANTIRESORPTIVES:&#xD;
&#xD;
          -  Use of calcitonin within 30 days prior to Screening Visit.&#xD;
&#xD;
          -  Fluorides &gt; 1 mg/day at any time prior to the study.&#xD;
&#xD;
          -  Strontium at pharmacologic dose at any time.&#xD;
&#xD;
        BISPHOSPHONATE USE as follows:&#xD;
&#xD;
          -  Any use within 90 days prior to the Screening Visit.&#xD;
&#xD;
          -  ≥ 2 weeks of use in the last year prior to the Screening Visit.&#xD;
&#xD;
          -  ≥ 3 months of use in the last 2 years prior to the Screening Visit.&#xD;
&#xD;
          -  ≥ 1 intravenous dose over the last 2 years prior to the Screening Visit.&#xD;
&#xD;
          -  ≥ 6 months of life-time exposure prior to the Screening Visit.&#xD;
&#xD;
        ESTROGENIC STEROIDS (Except for oral contraceptives):&#xD;
&#xD;
          -  Estrogenic steroids (HRT) within 60 days of the Screening Visit.&#xD;
&#xD;
          -  Selective estrogen receptor modulator (raloxifene) within 60 days of the Screening&#xD;
             Visit.&#xD;
&#xD;
        OTHER HORMONES:&#xD;
&#xD;
          -  Parathyroid hormone (PTH) within six months of the Screening Visit.&#xD;
&#xD;
          -  Use of any androgens, including prescription or nutritional supplement DHEA, within 30&#xD;
             days of the Screening Visit.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wallace Rheumatic Study Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peng T Fan, MD &amp; Wonil Lee, MD Partnership</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifestyles Health Science Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093-0943</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Rheumatology Group</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Rheumatology, Immunology and Arthritis</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of Central Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806-6264</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Medical Group, P.A.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Medical Research Group</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical School</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital, Division of Rheumatology</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Center for Arthritis Therapy</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group DBA</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Rheumatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immunology/Rheumatology Instituto Nacional de Ciencias Medicas y Nutricion, S.Z.</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2004</verification_date>
  <study_first_submitted>January 30, 2003</study_first_submitted>
  <study_first_submitted_qc>February 1, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2003</study_first_posted>
  <last_update_submitted>December 26, 2007</last_update_submitted>
  <last_update_submitted_qc>December 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Kenneth E. Schwartz, MD/Vice President, Medical Affairs</name_title>
    <organization>Genelabs Technologies, Inc.</organization>
  </responsible_party>
  <keyword>lupus</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <keyword>SLE</keyword>
  <keyword>bone loss</keyword>
  <keyword>DHEA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

